

$\beta$ -ENDORPHIN: DELETION OF A SINGLE AMINO ACID RESIDUE ABOLISHES  
IMMUNOREACTIVITY BUT RETAINS OPIATE POTENCY

Choh Hao Li, Wen-Chang Chang, Donald Yamashiro and  
Liang-Fu Tseng†\*

Hormone Research Laboratory  
and  
Department of Pharmacology†  
University of California  
San Francisco, CA 94143

Received February 21, 1979

**SUMMARY:** Two synthetic analogs of camel  $\beta$ -endorphin, one with omission of Leu-14 and the other with omission of Asn-20, have been assayed for immunoreactivity by radioimmunoassay, opiate activity in the guinea pig ileum preparation and analgesic potency in mice. It was found that the omission analogs had no immunoreactivity, but retained significant biological activities. As far as we are aware, this is the first instance in which deletion of a single amino acid residue in a biologically active peptide abolished immunoreactivity.

We have recently reported that the complete primary structure of  $\beta$ -endorphin is required for full analgesic activity (1). It is now found that deletion of a single amino acid residue in position 14 or 20 in the  $\beta_c$ -EP structure (see Fig. 1) does not alter its opiate potency, but causes a complete loss of immunoreactivity.

MATERIALS AND METHODS

$\beta_h$ -EP and  $\beta_c$ -EP were synthetic products as previously described (2, 3). The solid phase synthesis (4) of Des-Leu<sup>14</sup>- $\beta_c$ -EP and Des-Asn<sup>20</sup>- $\beta_c$ -EP was briefly described (5) and is detailed as follows. Synthesis was performed on Boc-Gln brominated polymer (0.50 mmole/g) (6) in a Beckman model 990 peptide synthesizer with a fully automated symmetrical anhydride program (1). In one synthesis Leu<sup>14</sup> of the  $\beta_c$ -EP sequence was omitted and in the other, Asn<sup>20</sup>. After removal of the last Boc group with trifluoroacetic acid and treatment with HF, the peptides

---

\*Present Address: Department of Pharmacology  
The Medical College of Wisconsin  
Milwaukee, Wisconsin 53233

Abbreviations:  $\beta_c$ -EP, camel pituitary  $\beta$ -endorphin;  $\beta_h$ -EP, human pituitary  $\beta$ -endorphin; RIA, radioimmunoassay.






Figure 2. Competition of Des-Leu<sup>14</sup>- $\beta_C$ -EP and Des-Asn<sup>20</sup>- $\beta_C$ -EP in the  $\beta_h$ -EP RIA. Final dilution of the antiserum was 1:3000.

in position 14 or 20 in  $\beta_C$ -EP abolished completely immunoreactivity in the  $\beta_h$ -EP RIA system.

In spite of its loss of immunoreactivity, the omission analogs possess high opiate activities as assayed *in vitro* by the guinea pig ileum method (7). It may be seen in Table 1 that both analogs are somewhat more active than the parent molecule. When the omission analogs were injected intracerebroventricularly in mice, they exhibited significant analgesic potency but less than that for  $\beta_C$ -EP (Table 2). The lack of correlation between the *in vitro* and *in vivo* assay results has also been observed in earlier studies with other synthetic analogs of  $\beta$ -EP (6, 12). This emphasizes the importance of evaluating the biological activity of an opioid peptide by both *in vivo* and *in vitro* procedures.

The data reported herein clearly show that immunoreactivity of  $\beta_C$ -EP can be dissociated completely from its biological activity. It is remarkable that deletion of a single amino acid

Table 1

Opiate Activity of Synthetic  $\beta_C$ -Endorphin Analogs  
by Guinea Pig Ileum Assay

Synthetic peptides	IC <sub>50</sub> <sup>a</sup>	Relative potency
$\beta_C$ -Endorphin	$9.1 \times 10^{-8}$	100
Des-Leu <sup>14</sup> - $\beta_C$ -EP	$6.5 \times 10^{-8}$	140
$\beta_C$ -Endorphin	$2.2 \times 10^{-8}$	100
Des-Asn <sup>20</sup> - $\beta_C$ -EP	$2.0 \times 10^{-8}$	110

<sup>a</sup> IC<sub>50</sub> in M

Table 2

Analgesic Potency of Synthetic  $\beta_C$ -Endorphin Analogs in Mice

Synthetic peptides	AD <sub>50</sub> <sup>a</sup>	Relative potency
$\beta_C$ -Endorphin	0.043 (0.035-0.075)	100
Des-Leu <sup>14</sup> - $\beta_C$ -EP	0.057 (0.033-0.093)	75
$\beta_C$ -Endorphin	0.026 (0.020-0.032)	100
Des-Asn <sup>20</sup> - $\beta_C$ -EP	0.057 (0.042-0.075)	46

<sup>a</sup> AD<sub>50</sub> in nmol/mouse (95% confidence limit)

residue in  $\beta_C$ -EP destroys its immunoreactivity. As far as we are aware, this is the first time it has been shown that omission of a single amino acid in a peptide is responsible for loss of immunoreactivity.

ACKNOWLEDGMENT: This work was supported in part by grants from NIMH (MH-30245 to C.H.L.) and NIDA (DA-01314 to L-F.T.).

## REFERENCES

1. Li, C. H., Tseng, L-F., and Yamashiro, D. (1978) *Biochem. Biophys. Res. Commun.* 85, 795-800.
2. Li, C. H., Yamashiro, D., Tseng, L-F., and Loh, H. H. (1977) *J. Med. Chem.* 20, 325-328.
3. Li, C. H., Lemaire, S., Yamashiro, D., and Doneen, B. A. (1976) *Biochem. Biophys. Res. Commun.* 71, 19-25.
4. Merrifield, R. B. (1963) *J. Am. Chem. Soc.* 85, 2149-2154.
5. Yamashiro, D. (1979) *Int. J. Peptide Protein Res.*, in press.
6. Yamashiro, D., Tseng, L-F., Doneen, B. A., Loh, H. H., and Li, C. H. (1977) *Int. J. Peptide Protein Res.* 10, 159-166.
7. Kosterlitz, H. W., Lydon, R. T., and Watt, A. F. (1970) *J. Pharmacol.* 39, 398-413.
8. Doneen, B. A., Chung, D., Yamashiro, D., Law, P. Y., Loh, H. H., and Li, C. H. (1977) *Biochem. Biophys. Res. Commun.* 74, 656-662.
9. D'Amour, F. E. and Smith, D. L. (1941) *J. Pharmacol. Exp. Ther.* 72, 74-79.
10. Li, C. H., Rao, A. J., Doneen, B. A., and Yamashiro, D. (1977) *Biochem. Biophys. Res. Commun.* 75, 576-580.
11. Chang, W-C., Yeung, H. W., and Li, C. H. (1979) *Int. J. Peptide Protein Res.*, in press.
12. Li, C. H., Yamashiro, D., Tseng, L-F., and Loh, H. H. (1978) *Int. J. Peptide Protein Research* 11, 154-158.